ScreenerHero

PHN Pharmanutra S.p.A.

BIT · IT · Healthcare · Drug Manufacturers - Specialty & Generic · pharmanutra.it
72.80EUR+0.41%Mkt Cap: 757.69M $P/E: 34.02

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internati…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap757.69M USD
Enterprise Value758.07M USD
Revenue (TTM)156.19M USD
Gross Profit111.81M USD
Net Income (TTM)21.74M USD
Revenue/Share15.00 EUR
Last Price72.80 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees144
CountryIT
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINIT0005274094
Valuation
P/E (Trailing)34.02
P/E (Forward)23.20
PEG—
EV/EBITDA21.01
EV/Revenue4.85
P/S4.83
P/B9.98
EPS (TTM)2.14
EPS (Forward)3.13
52W Range
43.5556% of range95.90
52W High95.90 EUR
52W Low43.55 EUR
Profitability
Gross Margin77.38%
Oper. Margin24.63%
EBITDA Margin23.10%
Profit Margin15.05%
ROE28.03%
ROA15.97%
Growth
Revenue Growth13.30%
Earnings Growth-5.30%
Cash Flow & Leverage
Operating CF21.26M USD
CapEx (TTM)3.41M USD
FCF Margin10.89%
FCF Yield2.24%
Net Debt3.50M USD
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity0.29
Current Ratio2.05
Quick Ratio1.51
Book Value/Sh7.26 EUR
Cash/Share1.58 EUR
Dividends
Fwd Div Rate1.20 EUR
Trail. Div Rate1.20 EUR
Div. Yield1.71%
5Y Avg Yield1.38%
Payout Ratio55.97%
Ex-Div DateMay 4, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)95.67 EUR
Upside (mean)+31.4%
Target Range92.00 EUR – 102.00 EUR
92.00+31.4% to mean102.00
# Analysts3
Ownership
Shares Out.9.58M
Float3.27M
Insiders65.02%
Institutions15.89%
Technical
SMA 5079.33 (-8.2%)
SMA 20076.82 (-5.2%)
Beta0.18
S&P 52W Chg16.45%
Avg Vol (30d)19.46K
Avg Vol (10d)19.26K
Technical Indicators
RSI (14)43.6
MACD-2.1831
MACD Signal-2.4671
MACD Hist.+0.2840
BB Upper78.19 EUR
BB Middle73.30 EUR
BB Lower68.40 EUR
BB Width13.34%
ATR (14)2.683 EUR
Vol Ratio (20d)0.36x